UNCY Unicycive Therapeutics
- 1.0900
- -0.0400-3.54%
- 1.0900
- 0.00000.00%
Unicycive Therapeutics News
Unicycive Therapeutics Q1 2024 GAAP EPS $(0.61) Misses $(0.15) Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.15) by 306.67 percent.
Unicycive Therapeutics 1Q Loss/Shr 61c >UNCY
Unicycive Therapeutics 1Q Loss/Shr 61c >UNCY
Unicycive Therapeutics | 10-Q: Quarterly report
Benchmark: Restated Unicycive Therapeutics (UNCY.US) rating and adjusted from Speculative Buy to Specified Buy, target price of $3.00.
Benchmark: Restated Unicycive Therapeutics (UNCY.US) rating and adjusted from Speculative Buy to Specified Buy, target price of $3.00.
Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics with a Speculative Buy and maintains $3 price target.
Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company or
Unicycive Therapeutics Initiated at Overweight by Piper Sandler
Unicycive Therapeutics Initiated at Overweight by Piper Sandler
Piper Sandler Initiates Coverage On Unicycive Therapeutics With Overweight Rating, Announces Price Target of $9
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Unicycive Therapeutics with a Overweight rating and announces Price Target of $9.
Unicycive Therapeutics: A Strong Buy on OLC's Potential to Revolutionize Hyperphosphatemia Treatment in CKD
CORRECTION: On Friday, Unicycive Therapeutics Reported Q4 EPS Of $(0.22), Which Missed $(0.17) Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.17) by 29.41 percent. This is a 56.86 percent increase over losse
Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of $4.50.
Unicycive Therapeutics Q4 EPS $(0.35) Misses $(0.17) Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.17) by 105.88 percent. This is a 31.37 percent increase over loss
Unicycive Therapeutics GAAP EPS of -$1.28, Revenue of $0.7M
Unicycive Therapeutics to Be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) today announced that multiple presentations will be delivered on the Company's product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAptorum Gr (NASDAQ:APM) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap stands at $33.0 million. Nuvectis Pharma (NASDAQ:NVCT) stock moved
Unicycive Therapeutics Announced It Has Entered Into A Securities Purchase Agreement With Certain Healthcare-focused Institutional Investors For The Sale Of 50,000 Shares Of Its Series B Convertible Preferred Stock At An Offering Price Of $1,000 Per Share
Unicycive Therapeutics Announced It Has Entered Into A Securities Purchase Agreement With Certain Healthcare-focused Institutional Investors For The Sale Of 50,000 Shares Of Its Series B Convertible P
Unicycive Announces $50 Million Private Placement
LOS ALTOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney
Buy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate Prospects
H.C. Wainwright analyst Ed Arce has maintained their bullish stance on UNCY stock, giving a Buy rating on March 11.
Unicycive Reports Progress in Kidney Injury Treatment Trial
Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a biotech firm focusing on kidney disease therapies, has reported successful completion of the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for UNI-494, a drug candidate aimed at preventing delayed graft function (DGF) after kidney transplantation.
Analysis
Price Target
No Data
